New Cannabis Ventures offers readers this easy-to-read exclusive summary of BDSA’s monthly cannabis sales data for 11 states.
Cannabis sales increased 5.3% in December compared to November according to cannabis data analytics firm BDSA. Looking at a per-day basis, sales increased 2.0% month-over-month. In this review, we will look at the markets one-by-one, beginning with the eastern markets and then concluding with the western markets. In total, BDSA estimates that sales across the 11 markets totaled $1.68 billion during the month.
BDSA provides coverage for Florida, Illinois, Maryland, Massachusetts, Michigan and Pennsylvania. In December, year-over-year growth ranged from -11.6% in Maryland to 32.0% in Michigan. Note that Florida, Maryland and Pennsylvania are medical-only markets, though Maryland is introducing adult-use soon.
Sales spiked 5.3% higher from November in December to $206.6 million, up 26.1% from a year ago and a new record month. Flower sales rose 29% from a year ago, while pre-rolls grew just 2%. Ingestibles gained 30%, and concentrates expanded by 25%.
We previously published data released by the state showing that sales rose 10.5% sequentially and 1.1% from a year ago. BDSA estimated sales of $175.3 million, in line with the state-released data. Flower sales were flat from a year ago, while pre-rolls grew 8%. Concentrate sales gained 4%, while ingestibles fell 3%.
The slumping Maryland medical market fell again from a year ago by 11.6% to $41.0 million, up 7.7% sequentially. Flower, down 16%, and pre-rolls, down 17%, were weak, while ingestibles fell just 1% from a year ago. Concentrates declined 9%.
Sales of $154.5 million rose 8.2% sequentially and fell 2.2% from a year ago. Flower sales grew 3% from December 2021, while pre-rolls fell by 3%. Concentrates sales were 6% lower, and ingestibles fell 4%.
We had previously written about data released by the state indicating that Michigan cannabis rose about 9% sequentially and grew 32% year-over-year. BDSA estimated sales similar to the state at $221.7 million. Flower sales grew 39% from a year ago, while pre-rolls soared 74%. Concentrates expanded by 14%, and ingestibles grew 23%.
Sales increased 9.8% sequentially to $102.4 million, which was down 5.1% from a year ago. Flower sales slipped 2%. Concentrates fell 9%, while ingestibles expanded by 4%.
BDSA provides coverage for Arizona, California, Colorado, Nevada and Oregon. In December, year-over-year growth ranged from -22.2% in California to -6.4% in Arizona compared to a year ago.
Combined sales of $108.6 million ticked 1.8% higher in December compared to November, but they fell 6.4% from a year ago. Medical sales of $38.8 million rose 3% sequentially and fell 30% from a year ago. Adult-use sales of $69.8 million increased 1% from November and 15% from a year ago. Flower sales fell 17% from a year ago, while pre-rolls soared 32%. Ingestibles gained 4%, and concentrates fell 6%.
California sales fell 0.6% sequentially and 22.2% from a year ago to $385.5 million. Flower sales fell 30%, while pre-rolls dropped 16%. Concentrates fell 21%, and ingestibles declined 14% from a year ago.
The first state with adult-use saw sales spike in December by 10.1% sequentially to $143.5 million, which was 14.6% lower than a year ago. Flower sales dropped 12% from a year ago, while pre-rolls fell 17%. Ingestibles were down 19%, and concentrates were 14% lower.
Nevada experienced a sequential decline of 2.5% as sales fell 22.1% from a year ago to $60.8 million. Flower plunged 31%, while pre-rolls fell 13%. Ingestibles dropped 17%, and concentrates declined by 13%.
Revenue grew 5.1% sequentially as it fell 10.4% from a year ago to $79.3 million. Flower sales dropped 20%, while pre-rolls gained 1%. Concentrates fell 10%, while ingestibles grew 8%.
For readers interested in a deeper look at cannabis markets across these eleven states and more, including segmentation by additional product categories, brand and item detail, longer history, and segmentation by product attributes, learn how BDSA Solutions can provide you with access to actionable data and analysis.